Literature DB >> 8815789

Defects in G protein-coupled signal transduction in human disease.

A M Spiegel1.   

Abstract

G proteins couple receptors for many hormones and neurotransmitters to effectors that regulate second messenger metabolism. G protein-coupled receptors comprise a superfamily with the common structural feature of a single polypeptide with seven membrane-spanning domains. G proteins themselves are heterotrimers with an alpha subunit that binds guanine nucleotides. In the basal state, G proteins tightly bind GDP; receptor activation allows exchange of bound GDP for GTP that activates the G protein and causes it to modulate effector activity. An intrinsic GTPase activity hydrolyzes bound GTP to GDP thereby deactivating the G protein. The effects (cholera, whooping cough) of bacterial toxins that target G proteins for covalent modification signal the potential importance of G protein dysfunction as a cause of human disease. Conceptually, G protein dysfunction could involve gain or loss of function. For Gs, examples of both types have already been defined. Mutations in G protein-coupled receptors have also been identified in several human diseases. Germline loss of function mutations in rhodopsin, cone opsins, the V2 vasopressin receptor, ACTH receptor, and calcium-sensing receptor are responsible for retinitis pigmentosa, color blindness, nephrogenic diabetes insipidus, familial ACTH resistance, and familial hypocalciuric hypercalcemia, respectively. Missense mutations that cause constitutive receptor activation have been identified in the TSH and LH receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815789     DOI: 10.1146/annurev.ph.58.030196.001043

Source DB:  PubMed          Journal:  Annu Rev Physiol        ISSN: 0066-4278            Impact factor:   19.318


  37 in total

1.  Modulation of histamine H(2) receptor signalling by G-protein-coupled receptor kinase 2 and 3.

Authors:  M S Rodriguez-Pena; H Timmerman; R Leurs
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Constitutively active mutants of 5-HT4 receptors are they in unique active states?

Authors:  S Claeysen; M Sebben; C Bécamel; M L Parmentier; A Dumuis; J Bockaert
Journal:  EMBO Rep       Date:  2001-01       Impact factor: 8.807

3.  How activated receptors couple to G proteins.

Authors:  H E Hamm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

4.  Ligand-receptor binding measured by laser-scanning imaging.

Authors:  P Zuck; Z Lao; S Skwish; J F Glickman; K Yang; J Burbaum; J Inglese
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 5.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 6.  Thyrotropin receptor mutations in thyroid diseases.

Authors:  P M Yen
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

Review 7.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

8.  The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells.

Authors:  Mark Cannon; Nicola J Philpott; Ethel Cesarman
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Ligand-induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its carboxyl-terminal tail.

Authors:  Cornelia Walther; Stefanie Nagel; Luis E Gimenez; Karin Mörl; Vsevolod V Gurevich; Annette G Beck-Sickinger
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

10.  Ligand-mimicking receptor variant discloses binding and activation mode of prolactin-releasing peptide.

Authors:  Daniel Rathmann; Diana Lindner; Stephanie H DeLuca; Kristian W Kaufmann; Jens Meiler; Annette G Beck-Sickinger
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.